Hepatitis G Virus Infection in Iranian Blood Donors and High-Risk Groups
Hepatitis Monthly: 9 (4); 282-286 Article Type: Research Article
April 24, 2009
November 16, 2009
A. et al. Hepatitis G Virus Infection in Iranian Blood Donors and High-Risk Groups,
Online ahead of Print
Background and Aims: Hepatitis G virus (HGV) has a worldwide distribution, and the prevalence rates among blood donors and high-risk groups are different. The purpose of this study was to assess the frequency of the HGV infection in blood donors as a blood borne pathogen and in high-risk groups (multitransfused patients), such as thalassemic, hemophillic, and hemodialysis patients.
Methods: 400 Iranian (Tehran Blood Transfusion Center, 2004) blood donors were tested for HGV RNA by a reverse transcriptase chain reaction (RT-PCR) method. The participants were negative in blood screening tests for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti- HCV), human immunodeficiency virus (HIV) Ag/Ab, and Rapid Plasma Reagin (RPR). HGV RNA positivity was surveyed in 40 thalassaemic, 16 hemophilic, and 46 hemodialysis patients by RT-PCR. To assess the frequency of infection, the prevalence of HGV RNA positive cases per 100 donors/patients with 95% confidence intervals (95% CI) were calculated. P values were estimated with chi-square tests.
Results: 19 (4.8%; 95% CI: 2.9-6.5%) out of 400 blood donors samples were HGV RNA positive. The prevalence of HGV infection was 5.28% (13 out of 243) in repeat donors, 4.12% (4 in 99) in lapsed donors, and 3.50% (2 out of 58) in first-time blood donors. The combined prevalence of HGV infection in these groups of patients was 16 (15.7%; 95% CI: 8.3-23.1%) out of 102 samples. HGV RNA frequency was 1 out of 40 (2.5%; 95% CI: 1.8-3.2%) thalassemic patients, 15 out of 46 (32.6%; 95% CI: 16.8-48.4%) hemodialysis patients, and 0 out of 16 hemophilics patients.
Conclusions: The prevalence of HGV RNA in the high-risk population was 15.7% and nearly 3 times more than blood donors (4.8%). These data indicate the possibility of parenteral transmission of HGV, especially by transfusion of blood and blood components. Decisions to screen blood supplies for a transfusion-transmitted infection agent should be based on sufficient benefits for recipients.
© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.